 | | Vol. 9.04 – 3 February, 2021 |
| |
|
|
| Researchers report a simple technique to simultaneously control the spatial and temporal self-organization of bacterial active matter. They confined dense active suspensions of Escherichia coli cells and manipulated a single macroscopic parameter through the addition of purified genomic DNA.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists report a longitudinal single-cell and repertoire profiling of the B cell response up to six months in mild and severe COVID-19 patients.
[Cell] |
|
|
|
| Investigators applied single-cell RNA sequencing to 284 samples from 196 COVID-19 patients and controls and created a comprehensive immune landscape with 1.46 million cells.
[Cell] |
|
|
|
| Researchers designed CRISPR RNAs specific for PB1 and highly conserved regions of PB2 of influenza virus, and against the replicase and nucleocapsid genes of SARS-CoV-2.
[Nature Biotechnology] |
|
|
|
| The authors observed that 13 of 17 patients with COVID-19 had stereotypic variable heavy chain antibody clonotypes directed against the receptor binding domain of SARS-CoV-2 spike protein.
[Science Translational Medicine] |
|
|
|
| Scientists describe a protein nanoparticle vaccine against SARS-CoV-2. The vaccine was based on the display of coronavirus spike glycoprotein receptor-binding domain on a synthetic virus-like particle platform, SpyCatcher003-mi3, using SpyTag/SpyCatcher technology.
[Nature Communications] |
|
|
|
| In response to the ongoing COVID-19 pandemic, investigators developed an infectious complementary DNA clone for SARS-CoV-2.
[Nature Protocols] |
|
|
|
| Researchers investigated the cross-reactivity of antibodies raised against the first SARS-CoV for their reactivity towards SARS-CoV-2.
[Cell Reports] |
|
|
|
| Scientists showed that SARS-CoV-2 infected cells of the human exocrine and endocrine pancreas ex vivo and in vivo. They demonstrated that human β-cells expressed viral entry proteins, and SARS-CoV-2 infected and replicated in cultured human islets.
[Nature Metabolism] |
|
|
|
| The authors examined the effects of SARS-CoV-2 spike protein S1 subunit on the pro-inflammatory responses in murine and human macrophages.
[Heliyon] |
|
|
|
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
| | Researchers developed a coordinated system of chronic virus and Mycobacterium tuberculosis (Mtb) infection that induced central clinical manifestations of coinfection, including increased Mtb burden, extra-pulmonary dissemination, and heightened mortality.
[Immunity] |
|
|
|
| Investigators generated monoclonal antibodies from memory B cells of one patient to investigate the B cell responses during active infection.
[Nature Communications] |
|
|
|
| Scientists adapted a three-dimensional Rotary Cell Culture System to model M. bovis BCG biofilm growth in low-shear detergent-free liquid suspension.
[npj Biofilms and Microbiomes] |
|
|
|
|
| The author gives an update on concepts informing how metabolic disorders and their comorbidities modify the susceptibility to, natural history and potential treatment of SARS-CoV-2 infection, with a focus on human biology.
[Cell Metabolism] |
|
|
|
| Scientists review the current knowledge about the cellular machinery that conjugates, recognizes, and disassembles Met1-linked ubiquitin chains, and discuss the function of this unique posttranslational modification in regulating inflammation, cell death and immunity to pathogens.
[Cell Death & Differentiation] |
|
|
|
|
| Revelation Biosciences, Inc. announced that it has been granted approval by the Bellberry Human Research Ethics Committee in Australia to add a multiple dose cohort to its Phase I clinical study of REVTx-99 in healthy volunteers.
[Revelation Biosciences, Inc. (BusinessWire, Inc)] |
|
|
|
| Immunome, Inc. announced that Abzena was selected as Immunome’s partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
[Immunome, Inc. (BusinessWire, Inc)] |
|
|
|
| Avid Bioservices, Inc. and Humanigen, Inc. announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19.
[Avid Bioservices, Inc. (BusinessWire, Inc)] |
|
| | | February 16, 2021
Virtual |
|
|
| | | | | UT Health Science Center at Tyler – Tyler, Texas, United States |
|
|
| | | University of Gothenburg – Gothenburg, Sweden |
|
|
| | | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
| | | University of Strasbourg – Strasbourg, France |
|
|
| | | Stanford School of Medicine – Stanford, California, United States |
|
|
| |
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
